The global oligonucleotide synthesis market is experiencing explosive growth, projected to surge from $8.8 billion in 2024 to a staggering $19.7 billion by 2029 at a compound annual growth rate of 17.5%. This meteoric rise is fueled by several key drivers.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Driving Forces Behind the Market’s Ascent
- Escalating use of synthesized oligonucleotides in therapeutic and diagnostic applications, harnessing their potential to tackle a diverse array of neurological disorders, rare diseases, and gene therapy.
- Continuous technological advancements, such as next-generation sequencing (NGS) and the revolutionary CRISPR gene-editing tool, which are catalyzing demand for oligonucleotide synthesis.
- Burgeoning investments from governments and major industry players in life science research and synthetic biology, paving the way for groundbreaking discoveries.
- A crescendoing focus on precision and personalized medicine, underscoring the indispensable role of oligonucleotides in tailoring treatments to individual genetic profiles.
Opportunities on the Horizon
Emerging economies, such as China, India, Japan, Brazil, and Argentina, present fertile ground for market growth, attracting substantial investments from leading companies seeking to expand their footprint in these regions. For instance, in 2023, Merck KGaA, a German biotechnology giant, invested $76 million to bolster production capabilities for high-purity reagents in Nantong, China.
Challenges and Complexities
While the market’s prospects are bright, challenges persist. Achieving precise control over oligonucleotide length while minimizing impurities poses a significant hurdle. Additionally, the generation of harmful waste during synthesis is an environmental concern that demands innovative solutions. Furthermore, the efficient delivery of oligonucleotide drugs to specific targets remains a formidable obstacle, with researchers actively exploring novel strategies, such as positively charged cell-penetrating peptides, to enhance drug bioavailability.
Key Players Shaping the Landscape
Major players in the oligonucleotide synthesis market include Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific, LGC Limited, Agilent Technologies, Inc., Kaneka Corporation, Maravai Lifesciences Holdings, Inc., Azenta, Inc., Twist Bioscience Corporation, and Genscript Biotech Corporation. In the therapeutic applications segment, prominent companies include Biogen Inc., Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Astrazeneca, Astellas Pharma Inc., Jazz Pharmaceuticals Plc, Nippon Shinyaku, Co. Ltd., Ionis Pharmaceuticals, Inc., and Novartis AG.
As the oligonucleotide synthesis market continues its upward trajectory, fueled by scientific breakthroughs and a growing recognition of its transformative potential, it stands poised to reshape the landscape of therapeutics, diagnostics, and personalized medicine.
